Generic Name:Nivolumab Indications Nivomab is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma: Non-Small Cell Lung Cancer (NSCLC): Malignant Pleural Mesothelioma: adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. Renal Cell Carcinoma (RCC): Classical Hodgkin Lymphoma (cHL): adult patients with classical Hodgkin lymphoma that has […]